Version 2 2024-06-06, 08:41Version 2 2024-06-06, 08:41
Version 1 2019-06-08, 12:45Version 1 2019-06-08, 12:45
journal contribution
posted on 2024-06-06, 08:41authored byAnthony Lamanna, Julian MaingardJulian Maingard, Hong Kuan Kok, Dinesh Ranatunga, Seamus T Looby, Paul Brennan, Michelle Chua, Andrew Owen, Duncan Mark Brooks, Ronil V Chandra, Hamed AsadiHamed Asadi
Vertebral compression fractures (VCFs) are a common cause of back pain and disability and are usually osteoporotic in nature. Therapy aims to adequately control pain and allow early mobilisation and return of function while preventing additional fractures. A proportion of patients do not achieve adequate pain relief using conservative measures alone. Unwanted adverse effects from medications may also ensue. Vertebroplasty represents an alternative treatment option for VCFs. Patients with acute VCFs (≤6 weeks old) may gain the most benefit from vertebroplasty as healed fractures are not as amenable to cement injection. High-quality studies have reported conflicting results regarding the use of vertebroplasty in the treatment of acute VCFs. Despite high-quality evidence, varying study designs and heterogenous patient cohorts make interpretation of this data difficult. Only one sham-controlled randomised controlled trial (RCT) has evaluated vertebroplasty exclusively in patients with acute VCFs, reporting favourable results. Pooled data from RCTs also suggest vertebroplasty to be safe. This article provides a concise and critical review of the current literature regarding vertebroplasty for the treatment of acute VCFs.